Redx Pharma PLC's (LON:REDX) chief scientific officer Dr Richard Armer speaks to Proactive London's Andrew Scott after announcing they'd won grant funding for their latest project.
They're collaborating with the Medicines Discovery Catapult, a government body that helps accelerate the discovery of new treatments and will focus on potential new drugs for idiopathic pulmonary fibrosis (IPF), a life-threatening fibrotic lung condition.